China Approves First Drug Targeting Cause of Narcolepsy

For the first time anywhere in the world, a medicine designed to restore the brain chemistry disrupted by narcolepsy has won regulatory approval.

China's National Medical Products Administration authorized oveporexton, marketed as Orzeyful, for treating narcolepsy type 1 in people aged 16 and older. The decision makes China the first country to approve an orexin receptor 2 agonist, introducing an entirely new class of medication that works differently from anything currently available.

Narcolepsy type 1 is a chronic neurological disorder that affects how the brain controls sleep and wakefulness. People with the condition experience overwhelming daytime sleepiness and cataplexy, a sudden loss of muscle control triggered by emotions like laughter or surprise.

The disorder represents about 60% to 70% of all narcolepsy diagnoses. Many people develop symptoms during their teens or twenties, though diagnosis often takes years because excessive sleepiness can resemble other sleep problems.

Current treatments help patients stay awake during the day or reduce cataplexy episodes, but they don't address the underlying cause. People with narcolepsy type 1 lack orexin, a brain chemical essential for maintaining wakefulness.

Oveporexton works by targeting orexin receptor 2, restoring the signaling pathway that the disease disrupts. Japanese pharmaceutical company Takeda says this mechanism sets the medicine apart because it addresses the biological process associated with narcolepsy rather than just managing individual symptoms.

The approval follows results from two global Phase 3 clinical trials called FirstLight and RadiantLight. Both studies met their primary goals, with participants receiving oveporexton experiencing significant improvements in daytime sleepiness compared with those taking a placebo.

People in the trials also reported fewer cataplexy episodes and better daily functioning. The company observed improvements in nighttime sleep and cognitive performance while maintaining a safety profile consistent with earlier studies.

Why This Inspires

China's role in this approval reflects how global collaboration in medical research can accelerate breakthroughs for people everywhere. Takeda conducted its development program across multiple countries simultaneously, and China's regulatory system moved quickly enough to become the first to complete its review.

"This indicates that in the field of the development of globally new drugs, China has achieved a historic breakthrough," said Xu Xiaoqiang, director of the Chemical Drugs Department at the Center for Drug Evaluation.

The U.S. Food and Drug Administration has accepted the application for Priority Review after granting Breakthrough Therapy designation. Japan is evaluating the treatment under its Sakigake fast-track program, with both reviews ongoing.

Takeda continues working with regulators in other markets as reviews proceed independently, with each country determining whether the medicine meets its own standards before making approval decisions.

For millions living with narcolepsy worldwide, this first approval signals hope that a treatment targeting the root cause may soon become available.